Sitting Down With... Ibraheem “Ibs” Mahmood, President and Chief Executive Officer, DrugDev, founded in the UK and headquartered in King of Prussia, PA, USA.

Manufacturers have gotten to grips with the complexities of batch-based bioprocesses, but breaking into the realm of continuous bioprocessing can lead to even greater efficiency.

Decisions around toxicology testing must be made using scientific methods, not emotions or politics.

Europe has set the stage for safer supply chains with its Falsified Medicines Directive. Next, the spotlight could fall on using serialization to boost patient centricity.

Amazing innovation is happening all around us in the pharma industry. We should take the time to look outside of our own unique areas to congratulate the efforts of others.

Will future drugs in Europe be priced based on therapeutic outcomes?

Will expanding the Priority Review Voucher scheme defeat its original purpose?

How difficult is it to develop a new drug? Statistics have the answer

The EMA says it will review its standards for first-in-human trials

A survey-based report highlights wildly inaccurate drug demand projections